This inventor holds 1 USPTO granted patent. Top assignee: Astrazeneca Ab. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Swantje Thiering: Innovator in Pharmaceutical Development
Introduction
Swantje Thiering, an accomplished inventor based in Gillingham, Dorset, GB, has made significant contributions to the field of pharmaceuticals. With her innovative approach to chemical processes, she has developed methods that enhance the manufacturing of valuable compounds.
Latest Patents
Swantje holds a patent for a novel process used in the production of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile, along with its pharmaceutically acceptable salts. This invention specifically focuses on the citrate form of the compound and introduces new intermediates that are essential for large-scale manufacturing, showcasing her dedication to advancing pharmaceutical production.
Career Highlights
Swantje is associated with AstraZeneca AB, a global leader in the pharmaceutical industry. Her work at AstraZeneca reflects her commitment to developing innovative solutions that address healthcare challenges. The success of her patent emphasizes her role in the ongoing evolution of drug development and production.
Collaborations
Throughout her career, Swantje has collaborated with notable colleagues, including Vern Delisser and Martin Hedberg. These partnerships have allowed for the cross-pollination of ideas and the development of cutting-edge processes that drive the industry forward.
Conclusion
In conclusion, Swantje Thiering's contributions to pharmaceutical innovations demonstrate her invaluable role as an inventor. Her patent for the new process in manufacturing key compounds is a testament to her expertise and dedication to improving healthcare through science. As she continues her work at AstraZeneca, her future endeavors hold the promise of further breakthroughs in the pharmaceutical sector.